Phathom Pharmaceuticals, Inc. — Director's Dealing 2021

Jun 11, 2021

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Phathom Pharmaceuticals, Inc. (PHAT)
CIK: 0001783183
Period of Report: 2021-06-04

Reporting Person: Guzzo Anthony J. (VP, Chief Accounting Officer)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	804	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Stock Option (Right to Buy)	$25.06	2030-03-31	Common Stock (57500)		Direct
Stock Option (Right to Buy)	$32.20	2030-06-30	Common Stock (12000)		Direct
Stock Option (Right to Buy)	$39.11	2031-01-27	Common Stock (24250)		Direct

Footnotes

F1: These shares were acquired under the Phathom Pharmaceuticals, Inc. employee stock purchase plan on January 14, 2021.

F2: The option vested with respect to 25% of the shares of common stock on March 16, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.

F3: The option will vest with respect to 25% of the shares of common stock on July 1, 2021, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.

F4: The option will vest with respect to 25% of the shares of common stock on January 28, 2022, and will vest with respect to the remaining shares in equal monthly installments over the following three years, subject to the reporting person's continuous service to the Issuer on the applicable vesting dates.